Who can use Mylotarg(Gemtuzumab ozogamicin)?

Gemtuzumab ozogamicin is a CD33-directed antibody and cytotoxic drug conjugate indicated for:

1. Treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and children aged 1 month and above.

2. Treatment of relapsed or refractory CD33-positive acute myeloid leukemia (AML) in adults and children aged 2 years and above.

Related Columns

Gemtuzumab ozogamicin(Mylotarg)

Gemtuzumab ozogamicin is a CD33-directed antibody and cytotoxic drug conjugate...

WeChat Scan
Free Inquiry

What Are the Indications for Gemtuzumab (Mylotarg)?

Gemtuzumab (Mylotarg) is an innovative CD33-directed antibody-drug conjugate (ADC) that plays a crucial role in the treatment of acute myeloid leukemia (AML). As a targeted therapy, it combines the sp...

What is Inotuzumab ozogamicin (Besponsa)?

Inotuzumab ozogamicin (Besponsa) is an antibody-drug conjugate (ADC) targeting CD22. It achieves targeted elimination of cancer cells by precisely acting on the CD22 antigen expressed on the surface o...

Gemtuzumab instructions, medical insurance, price, efficacy, adverse reactions

Mylotarg is a monoclonal antibody drug targeting CD33 antigen, developed and produced by Pfizer in the United States. Its main ingredient is gemtuzumab, and the dosage form is lyophilized powder injec...

Indications of Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is a targeted therapy for CD33-positive acute myeloid leukemia with a wide range of indications and significant therapeutic effects. Patients should also focus on maintaining a h...